完整後設資料紀錄
DC 欄位語言
dc.contributor.authorHuang, Chih-Yuen_US
dc.contributor.authorChen, Li-Hsunen_US
dc.contributor.authorHuang, Hsuan-Yuen_US
dc.contributor.authorKao, Feng-Shengen_US
dc.contributor.authorLee, Yun-Taen_US
dc.contributor.authorSelvaraju, Manikandanen_US
dc.contributor.authorSun, Chung-Mingen_US
dc.contributor.authorChen, Hueih-Minen_US
dc.date.accessioned2019-04-03T06:38:47Z-
dc.date.available2019-04-03T06:38:47Z-
dc.date.issued2015-01-01en_US
dc.identifier.issn2046-2069en_US
dc.identifier.urihttp://dx.doi.org/10.1039/c5ra06095hen_US
dc.identifier.urihttp://hdl.handle.net/11536/127954-
dc.description.abstractA simple protocol for the synthesis of quinic acid derivatives was established and their biological evolution against T-cells is studied. Results showed that one of the derivatives, Cyn-1324, has low toxicity on T-cells and a high effect on reducing Signal 2 of T-cell immune responses. In vitro binding measurements of atomic force spectroscopy further indicated that the blocking effect of Cyn-1324 between CD28 and CD80 was about 31 + 4%. In vivo animal tests also confirmed that Cyn-1324 can reduce the allergic responses from ovalbumin-induced mice with little toxicity. Based on these observations, Cyn-1324 can be a mild immuno-suppressive candidate for future drug development.en_US
dc.language.isoen_USen_US
dc.titleParallel synthesis and biological evolution of quinic acid derivatives as immuno-suppressing agents against T-cell receptorsen_US
dc.typeArticleen_US
dc.identifier.doi10.1039/c5ra06095hen_US
dc.identifier.journalRSC ADVANCESen_US
dc.citation.volume5en_US
dc.citation.issue63en_US
dc.citation.spage50801en_US
dc.citation.epage50806en_US
dc.contributor.department應用化學系zh_TW
dc.contributor.departmentDepartment of Applied Chemistryen_US
dc.identifier.wosnumberWOS:000356303000019en_US
dc.citation.woscount0en_US
顯示於類別:期刊論文


文件中的檔案:

  1. ef8d90c478b9a8e26a0f2c4e023504f9.pdf

若為 zip 檔案,請下載檔案解壓縮後,用瀏覽器開啟資料夾中的 index.html 瀏覽全文。